Pharma/BioPharma Users Meetings

Introduction

Introduction

Join our Pharma/BioPharma Users Meetings in San Diego, San Francisco, and Boston/Cambridge.

San Diego

San Diego
October 5, 2022, 1:00 - 5:00 pm

The Lodge at Torrey Pines

11480 North Torrey Pines Road, La Jolla, California 92037

1:00 - 1:15 pm Welcome and Introduction: SoCal Bruker User's Meeting
Liliane Soares, Account Manager, Bruker Daltonics, USA

1:15 - 1:30 pm Bruker’s Commitment to Pharma/Biopharma
Mike Greig, Director, Pharma/BioPharma Americas, Bruker Daltonics, USA 

1:30 - 2:00 pm Combining Patch Clamping Electrophysiology and Proteomic Mass Spectrometry on Live Brain Tissue Slices (PatchC-MS)
Prof. John Yates, Ph.D., Department of Molecular Medicine, Scripps Research, La Jolla, CA, USA
As interest in single-cell analysis increases, performing single cell MS still remains a challenge. We performed single-cell patch-clamp electrophysiology combined with mass spectrometry proteomic analysis in live brain tissue slices to combine functional data with molecular mechanisms.

2:00 - 2:30 pm Two Sides of Precision Medicine: Individualizing Assessment and Therapies
Jennifer van Eyk, Ph.D., Director, Precision Biomarker Laboratories, Cedars-Sinai Medical Centre, Los Angeles, USA
The premise of precision medicine remains the  identification of treatable diagnosis for each specific individual. To accomplish this requires i) having an array of mechanistic therapies for each disease that can be harnessed for an individual and ii) a means to diagnosis (identify) which therapy (or combination) will be appropriate to treat a specific target person. Our group has been  developing scalable proteomics methods for high-through methods for mechanistic drug screening on iPSC-derived cultured tissue which can act as avatars of the person. Simultaneously, we have been developing proteomic pipelines for single cell isolated from tissue biopsies from target individuals who could be beneficial from the assignment of the appropriate drug treatment. The goal is to move forward with clinical deployment by addressing both individual’s assessment and development of individual mechanistic treatments.

2:30 - 3:00 pm Break

3:00 - 3:15 pm Streamlined & automated sample processing for in-depth proteomic analyses
Garwin Pichler, Ph.D., Managing Director, PreOmics, Planegg/Martinsried, Germany
Proteomics workflows are becoming increasingly important for applications such as biomarker discovery, validation and drug compound screening. Proteomics workflows have been traditionally limited by LC-MS measurement time and sample preparation throughput. While advances in LC-MS instrument technologies and workflows have now significantly increased the number of samples that can be processed on a weekly basis, the bottleneck has shifted to efficient, robust, and reliable high-throughput sample preparation. PreOmics’ improved sample technology enables robust and reproducible sample preparation, resulting in reliable biological outcomes. The iST sample processing technology provides significant time savings and can be fully automated, In addition, our new BeatBox technology enables very efficient tissue homogenization and cell lysis for up to 96 samples.

3:15 - 3:40 pm Expanding the Targeted Protein Degradation ToolBox with High-throughput DIA Proteomics
Alex Campos, Ph.D., Senior Director Proteomics Platform, Plexium, San Diego, CA, USA

3:40 - 4:10 pm Break

4:10 - 4:40 pm Large-Scale Mass Spectrometry Profiling for Accelerated Biomarker Discovery
Jeramie Watrous, Ph.D., Co-Founder and Head of Analytical R&D, Sapient, San Diego, CA, USA
In this session, Sapient will discuss how its next-generation mass spectrometry-based platform is revolutionizing the discovery of small molecule biomarkers to transform patient selection, disease diagnosis, and drug development. Learn how these rapid liquid chromatography-mass spectrometry (rLC-MS) systems enable untargeted capture and measure of >11,000 circulating factors per biosample, and see examples of the high quality, reproducible data they generate to reveal specific biomarkers that can be used to align patients, disease biology, and specific therapies.

4:40 - 5:00 pm TBD

San Francisco

South San Francisco
October 6, 2022, 10:30 am - 3:00 pm

Embassy Suites by Hilton SFO

250 Gateway Blvd, South San Francisco, CA

10:30 - 10:45 am Welcome and Introduction: NorCal Bruker User's Meeting
Liling Fang, Ph.D., Sr. Sales Account Manager, Bruker Daltonics, USA

10:45 - 11:00 am Bruker’s Commitment to Pharma/Biopharma
Mike Greig, Director, Pharma/BioPharma Americas, Bruker Daltonics, USA 

11:00 - 11:30 am Combining Patch Clamping Electrophysiology and Proteomic Mass Spectrometry on Live Brain Tissue Slices (PatchC-MS)
Prof. John Yates, Ph.D., Department of Molecular Medicine, Scripps Research, La Jolla, CA, USA
As interest in single-cell analysis increases, performing single cell MS still remains a challenge. We performed single-cell patch-clamp electrophysiology combined with mass spectrometry proteomic analysis in live brain tissue slices to combine functional data with molecular mechanisms.

11:30 - 11:45 am New Methods Enable Deep Proteomics from FFPE Preserved Human Tumor Biopsies
Paul Schnier, Ph.D., Senior Director, Discovery Proteomics and Mechanistic Biology, Loxo Oncology, San Francisco, CA, USA
Formalin-fixed paraffin-embedded (FFPE) tissue preservation is the “gold-standard”  for tumor biopsy preservation. Although FFPE tumor tissues are widely available, they are rarely used in proteomic studies because of poor sensitivity and formalin-fixation artifacts. Here we demonstrate a novel sample preparation methodology and enrichment strategy that facilitates deep proteomic studies of FFPE-preserved colorectal human tumor biopsy slides.  We will illustrate how this chemistry coupled with the unprecedented sensitivity of the TimsTOF SCP instrument allows proteomic coverage similar to that attainable with fresh/frozen tissues for biomarker and target discovery.

11:45 - 12:45 pm Lunch

12:45 - 1:00 pm Imaging mass spectrometry in drug discovery
Kerri Grove, Ph.D., Investigator, Novartis, Emeryville, CA, USA
The presentation will show how imaging mass spectrometry is being used to support drug discovery. Quantitative measurements that retain spatial information can add valuable insight to traditional PK/PD studies. I will highlight several programs where imaging mass spectrometry played a key role in decision making for project teams

1:00 - 1:15 pm Bruker timsTOF fleX: A Multi-omics Tool for Small Pharma
Joey C. Latham, Ph.D., Senior Director, Bioanalytical Science, PTC Therapeutics, Mountain View, CA, USA
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. As a small pharmaceutical company specializing in rare diseases, every effort is made to maximize data generation from samples limited in size and number. Being able to perform investigational deep dives into the underlying biology of rare diseases helps us develop more efficacious therapies. My group at PTC Therapeutics develops analytical strategies compatible with diverse technologies that enable multi-omic analyses from limited sample requirements. The Bruker timsTOF fleX has become an integral part of our workflow. Here I highlight some of our current applications of the timsTOF fleX in better understanding rare disease pathophysiology.  

1:15 - 1:30 pm Streamlined & automated sample processing for in-depth proteomic analyses
Garwin Pichler, Ph.D., Managing Director, PreOmics, Planegg/Martinsried, Germany
Proteomics workflows are becoming increasingly important for applications such as biomarker discovery, validation and drug compound screening. Proteomics workflows have been traditionally limited by LC-MS measurement time and sample preparation throughput. While advances in LC-MS instrument technologies and workflows have now significantly increased the number of samples that can be processed on a weekly basis, the bottleneck has shifted to efficient, robust, and reliable high-throughput sample preparation. PreOmics’ improved sample technology enables robust and reproducible sample preparation, resulting in reliable biological outcomes. The iST sample processing technology provides significant time savings and can be fully automated, In addition, our new BeatBox technology enables very efficient tissue homogenization and cell lysis for up to 96 samples.

1:30 - 2:00 pm Break

2:00 - 2:15 pm Enhanced nano-bio interaction for deep and comprehensive plasma proteomic analysis with the Proteograph Product Suite
Daniel Hornburg, Ph.D., Vice President Proteomics, Seer Inc., Redwood City, CA, USA
The Proteograph Product Suite provides a new avenue for deep access to the high dynamic range of complex proteomes like plasma. Deep quantitative plasma proteome profiling across thousands of proteins and tens of thousands of peptides, using multiple distinctly functionalized nanoparticles, enables a high-resolution view of the proteome. Seer’s proprietary engineered nanoparticle technology captures low abundance proteins like chemokines and cytokines, and provides a platform for scalable biomarker discovery.

2:15 - 2:45 pm Two Sides of Precision Medicine: Individualizing Assessment and Therapies
Jennifer van Eyk, Ph.D., Director, Precision Biomarker Laboratories, Cedars-Sinai Medical Centre, Los Angeles, USA
The premise of precision medicine remains the  identification of treatable diagnosis for each specific individual. To accomplish this requires i) having an array of mechanistic therapies for each disease that can be harnessed for an individual and ii) a means to diagnosis (identify) which therapy (or combination) will be appropriate to treat a specific target person. Our group has been  developing scalable proteomics methods for high-through methods for mechanistic drug screening on iPSC-derived cultured tissue which can act as avatars of the person. Simultaneously, we have been developing proteomic pipelines for single cell isolated from tissue biopsies from target individuals who could be beneficial from the assignment of the appropriate drug treatment. The goal is to move forward with clinical deployment by addressing both individual’s assessment and development of individual mechanistic treatments.

2:45 - 3:00 pm Close
Liling Fang, Ph.D., Sr. Sales Account Manager, Bruker Daltonics, USA

Cambridge

Cambridge
October 13, 2022, 9:30 am - 2:30 pm

Hyatt Regency Cambridge 

575 Memorial Dr, Cambridge, MA 02139

9:30 - 9:45 am Welcome and Introduction: Boston/Cambridge Bruker User's Meeting
Robert Kane, Account Manager, Pharma/BioPharma, Bruker Daltonics, USA

9:45 - 10:00 am Bruker’s Commitment to Pharma/Biopharma
Mike Greig, Director, Pharma/BioPharma Americas, Bruker Daltonics, USA 

10:00 - 10:45 am Driving biology with sensitive and high-throughput proteomics
Nikolai Slavov, Ph.D., Director of Single Cell Proteomics Center, Allen Distinguished Investigator, Northeastern University, Boston, MA, USA 

10:45 - 11:00 am Social Tea/Coffee time

11:00 - 11:30 am Streamlined & automated sample processing for in-depth proteomic analyses
Russell Golson, Chief Commercial Officer, PreOmics, München, Germany

11:30 - 12:30 pm Lunch

12:30 - 1:00 pm MALDI imaging of untargeted small molecules and targeted proteins using MALDI-based immunohistochemistry (MALDI HiPLEX-IHC)
Mark Lim​, Ph.D., Executive Vice President and Chief Scientific Officer, AmberGen Inc., Watertown, MA, USA

1:00 - 1:30 pm Development and Application of LC-IMS-MS Lipidomics to Drug Discovery in Metabolic Diseases
Natalie Daurio, Ph.D., Principle Scientist, Pfizer, Cambridge, MA, USA

1:30 - 2:00 pm Large-Scale Mass Spectrometry Profiling for Accelerated Biomarker Discovery​
Philip Worboys, Ph.D., Head of Translational Science, Sapient, San Diego, CA, USA

2:00 - 2:30 pm Oligoquest
Mike Greig, Director, Pharma/BioPharma Americas, Bruker Daltonics, USA

 

For Research Use Only. Not for use in clinical diagnostic procedures.